Showing 8921-8930 of 19239 results for "".
- Life Goals and Their Changes Drive Successhttps://reachmd.com/news/life-goals-and-their-changes-drive-success/2462819/“Where is my life going?” “Who do I want to be?” The existence of high prestige and education goals, as well as their positive development, can drive success. As future-thinkers, adolescents spend significan
- Electronic Medical Tool Helps Clinicians Diagnose MPoxhttps://reachmd.com/news/electronic-medical-tool-helps-clinicians-diagnose-mpox/2462609/Diagnosing infectious conditions can be challenging. Diagnosis is especially challenging for uncommon and emerging infectious diseases for which there’s limited clinical experience. Nevertheless, successfully identifying patients with infectious diseases, especially communicable ones, i
- Electronic Medical Tool Helps Clinicians Diagnose MPoxhttps://reachmd.com/news/electronic-medical-tool-helps-clinicians-diagnose-mpox/2462614/Diagnosing infectious conditions can be challenging. Diagnosis is especially challenging for uncommon and emerging infectious diseases for which there’s limited clinical experience. Nevertheless, successfully identifying patients with infectious diseases, especially communicable ones, i
- Too Few Caregivers and Too Many Patients – a Bad Combination for Elderly in Rural Areashttps://reachmd.com/news/too-few-caregivers-and-too-many-patients-a-bad-combination-for-elderly-in-rural-areas/2457474/Too few caregivers and too many patients – a bad combination for elderly in rural areas Elderly people living in rural areas in Norway have higher mortality rates i
- Op-Ed: Practical Advice About Money in Residencyhttps://reachmd.com/news/op-ed-practical-advice-about-money-in-residency/2457398/Background: I went straight through with my education and while I’ve learned about science, humanities, and medicine; one topic that was rarely addressed for its importance was finance. We are trained to be physicians, but we do
- Study Looks at Cancer Prevention from the Perspective of People Experiencing Homelessnesshttps://reachmd.com/news/study-looks-at-cancer-prevention-from-the-perspective-of-people-experiencing-homelessness/2457047/Cancer is twice as likely to affect people experiencing homelessness (PEH) as members of the housed population. The disease is the second most common cause of death among PEH, a group that is underserved when it comes to medical care. At the same time, there i
- HER2+ Syngeneic Murine Models for Brain Metastasis and CNS Drug Testinghttps://reachmd.com/news/her2-syngeneic-murine-models-for-brain-metastasis-and-cns-drug-testing/2486329/Investigators report engineering immunocompetent, syngeneic murine mammary carcinoma models to express human HER2 (wild-type and the exon 20 insertion HER2YVMA) and to track spontaneous brain metastasis using a GFP tag. Using both 4T1 (BALB/c background) and EO771 (C57BL/6 background) backb
- Navigating the New COPD Era: Biologics, Guidelines, and Clinical Challengeshttps://reachmd.com/news/navigating-the-new-copd-era-biologics-guidelines-and-clinical-challenges/2484584/Dupilumab has emerged as a practice-changing option for patients with eosinophilic COPD, offering targeted anti–type 2 pathway therapy for those who continue to have frequent exacerbations despite optimized inhaled regimens; this development expands treatment choices for a high-risk
- A Paradigm Shift: Non-Opioid Alternatives in Pain Managementhttps://reachmd.com/news/a-paradigm-shift-non-opioid-alternatives-in-pain-management/2483366/The current landscape of pain management is fraught with challenges. Opioids, while effective for acute and some types of severe pain, carry risks of misuse, addiction, and overdose. These realities have intensified interest in non-opioid approaches that aim to relieve pain while minimizing
- Oral GLP-1 Hits Phase 3 Trial Targets; Regulatory Submissions Cominghttps://reachmd.com/news/oral-glp-1-hits-phase-3-trial-targets-regulatory-submissions-coming/2483149/Eli Lilly and Company announced positive topline results from its Phase 3 ATTAIN-2 trial, showing that its investigational oral GLP-1 receptor agonist, orforglipron, achieved significant weight loss and improved cardiometabolic outcomes in adults with obesity or overweight status and type 2 diabe